Researchers at the University of Zurich and from IBM Research have investigated the varying composition of cancer and immune cells in over 100 breast tumors. They’ve found that aggressive tumors are often dominated by a single type of tumor cell. If certain immune cells are present as well, an immune therapy could be successful for a specific group of breast cancer patients.
Every year more than 1.7 million women all over the world are diagnosed with breast cancer, with the disease ending fatally for around a half-million patients. In the fight against breast cancer, research is underway into novel therapeutic approaches that are designed to target cancer cellsmore precisely and also activate the tumor-associated immune system. So far, however, little is known about the cancer and immune cell types present within a tumor, and how they differ from patient to patient.
Mass cytometry unravels diversity of cells
Johanna Wagner of the University of Zurich joined forces with Marianna Rapsomaniki of IBM Research in Rüschlikon and the Patients’ Tumor Bank of Hope to use mass cytometry to examine several million cancer and immune cells from 140 patients as the basis for an atlas of tumor and immune cells. “Using this technology we were able to examine the diversity of cancer cells very precisely and describe how many different types of cancer cells are present in a tumor,” explains Wagner, who’s working on her Ph.D. under the supervision of Bernd Bodenmiller, professor at the new Department of Quantitative Biomedicine, whose group specializes in the precision medicine analysis of tissues.
In parallel to this, they also analyzed the immune system’s tumor-associated macrophages and T-cells, which could attack the tumor—but also support it. If the activated immune system launches a successful attack, the breast cancer cells are destroyed. But if the nearby immune cells are inactivated, the breast cancer cells survive the attack.
Every tumor is unique in terms of its cellular composition
The researchers discovered that the previous assumption that a greater diversity of tumor cells was present in more aggressive tumors was false. More aggressive tumors are in most cases dominated by one single type of tumor cell, which often displays a high degree of abnormality. “Every tumor we looked at was unique in terms of its cellular composition, which varied from patient to patient. This could be one of the reasons why we’re having such difficulty treating breast cancer,” says Wagner.
Breast cancer patients could benefit from immune therapy
At the same time, the scientists discovered similarities in the tumor-associated immune system between the aggressive tumors. Among one group of breast cancer patients they found an accumulation of inactive immune cells that are successfully activated by immune therapy to fight lung and skin cancer. This included patients who previously weren’t considered suitable candidates for immune therapy to treat breast cancer.
A comprehensive analysis of a tumor’s entire cancer and immune cells could thus be a good basis for therapies in precision medicine. “Our findings suggest that immune therapy might possibly work for breast cancer. We’ll be doing further studies on this, and if they’re successful will extend them into a clinical trial,” explains Professor Bodenmiller.